Methods of treating cancer by administering IGF-IR binding molecules
US10221232B2 · kind B2 · utility
7Cited by
65References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 12, 2017 |
| Grant date | Mar 5, 2019 |
| Priority date | — |
| Expiry date | Jan 12, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC40B40/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.